GENMAB A
corporate_fare Company Profile
GENMAB A (NASDAQ:GMAB) is a publicly traded company in the Life Sciences sector. Wiseek monitors GMAB SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.
Recent high-impact activity:
- DARZALEX Q2 Sales Hit $4.2B, Up 46% YoY, Boosting Genmab Royalties
- EC Approves Genmab's TEPKINLY for Relapsed/Refractory Follicular Lymphoma, First Bispecific Option
- Epcoritamab Phase 3 Smashes Primary Endpoint, Cuts DLBCL Progression Risk by 60%
- Epcoritamab Monotherapy Achieves 67% ORR in Elderly DLBCL, Genmab Reports
- Genmab Reports Strong Q1 Revenue Growth Amidst Strategic Investments and Mixed Clinical Data
Financial Snapshot
Dilution Risk
Low riskFiling-implied dilution signals for GMAB, detected from its recent SEC filings · based on capital-structure filings through 2026-03-16.
Share Buyback Program Completed · Significant Repurchase Value
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
GMAB files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.